Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Distinct Survivals and Optimal Combination of Immunotherapy Plus Immunophenotype in Uncommon and 20ins EGFR-mut Lung Adenocarcinoma: a Retrospective Multi-center Study

NCT06164574 is registered in ClinicalTrials.gov with Haiquan Chen as lead sponsor.

NCT NCT06164574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06164574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Distinct Survivals and Optimal Combination of Immunotherapy Plus Immunophenotype in Uncommon and 20ins EGFR-mut Lung Adenocarcinoma: a Retrospective Multi-center Study
Lead sponsor
Haiquan Chen
Phase
Observational
Overall status
Completed
Start date
November 1, 2022
Completion date
November 29, 2023
Enrollment
627 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer